SynopsisAflibercept, sold under the brand names Eylea and Zaltrap, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. The global Aflibercept Drug market was valued at US$ 5617 million in 2023 and is anticipated to reach US$ .....
SynopsisArcalyst, is a medication used to treat cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome, and Muckle–Wells syndrome; deficiency of interleukin-1 receptor antagonist; and recurrent pericarditis. The global Arcalys.....
SynopsisRilonacept, sold under the brand name Arcalyst, is a medication used to treat cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome, and Muckle–Wells syndrome; deficiency of interleukin-1 receptor antagonist; and recurrent .....
SynopsisEnbrel is a biopharmaceutical that treats autoimmune diseases by interfering with tumor necrosis factor (TNF, a soluble inflammatory cytokine) by acting as a TNF inhibitor. The global Enbrel market was valued at US$ 8764 million in 2023 and is anticipate.....
SynopsisEtanercept, sold under the brand name Enbrel among others, is a biopharmaceutical that treats autoimmune diseases by interfering with tumor necrosis factor (TNF, a soluble inflammatory cytokine) by acting as a TNF inhibitor. The global Etanercept Drugs m.....
SynopsisALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with hemophilia B. The global Alprolix market was valued at US$ 897 million in 2023 and is anticipate.....
SynopsisElocta is a medicine used to treat and prevent bleeding in patients with haemophilia A (an inherited bleeding disorder caused by lack of factor VIII). The global Elocta and Eloctate market was valued at US$ 1420 million in 2023 and is anticipated to reac.....
SynopsisFc Fusion Protein can used for haemophilia A and Hemophilia B The global Fc Fusion Protein for Haemophilia market was valued at US$ 2317 million in 2023 and is anticipated to reach US$ 3441.4 million by 2030, witnessing a CAGR of 5.0% during the forecast.....
SynopsisTrulicity (dulaglutide) is a diabetes medication for adults with type 2 diabetes that is injected once a week to help lower blood sugar. The global Trulicity market was valued at US$ 6741 million in 2023 and is anticipated to reach US$ 13270 million by 2.....
SynopsisTrulicity (dulaglutide) is a diabetes medication for adults with type 2 diabetes that is injected once a week to help lower blood sugar. The global Fc Fusion Protein for Diabetes market was valued at US$ 6741 million in 2023 and is anticipated to reach U.....
